ReviewInfectious disease clinics of North America2016
Cryptococcosis.
Review in Infectious disease clinics of North America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 372 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
372 citing papers in PubMed, 1 synthesis or guideline pooled it, 672 citations in OpenAlex.
- Single nucleotide polymorphisms are associated with strain-specific virulence differences among clinical isolates of Cryptococcus neoformans.Nature communications · 2024Pooled it
- A Crateriform Facial Nodule in a Man With Pulmonary Tuberculosis.International journal of dermatology · 2026Article
- IPMK at the crossroads of cellular signaling in health and disease.FEBS letters · 2026Review
- Synchronous Mucocutaneous Paracoccidioidomycosis and Oral Squamous Cell Carcinoma: Report of Two Rare Cases.Journal of cutaneous pathology · 2026Article
- Analytical Performance and Clinical Evaluation of a Fully Automated Multiplex RT-qPCR Platform for Rapid Detection of Central Nervous System Pathogens.Microorganisms · 2026Article
- Cryptococcal Infection Across Disease Stages: Host-Pathogen Interactions, Tissue Niches, and Translational Priorities.Pathogens (Basel, Switzerland) · 2026Review
- Species-Dependent Antifungal Profiles of Chitosan and Sulphated Polysaccharide-Rich Extract fromMarine drugs · 2026Article
- Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection.PLoS neglected tropical diseases · 2026Article
- Temporal shifts in adaptive immunity drive HIV-associated cryptococcal IRIS: mechanisms, models, and therapeutic opportunities.NeuroImmune pharmacology and therapeutics · 2026Article
- Characteristics of Mortality in HIV-negative Cryptococcosis Patients: Analysis of a Cohort of 743 Patients.Open forum infectious diseases · 2026Article
- Article
- Immunological mechanism behind reactivated cryptococcosis in persistently infected mice following FTY720 treatment.Infection and immunity · 2026Article
- Epidemiology and Clinical Features of Cryptococcosis Among Individuals Without HIV Infection: An Observational International Multicenter Study (MSG-11).Open forum infectious diseases · 2026Article
- Diagnosis of a patient with pulmonary and skeletal cryptococcosis: A case report and literature review.The Journal of international medical research · 2026Review
- PDE4B deficiency aids macrophage differentiation and contributes to Cryptococcus neoformans brain infection.PLoS pathogens · 2026Article
- Rituximab-associated cryptococcal meningitis in systemic lupus erythematosus: A case report.Medical mycology case reports · 2026Article
- Article
- Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi.Cell · 2026Article
- Successful desensitization to liposomal amphotericin B for the treatment of disseminated cryptococcosis in pregnancy: a case report.ASM case reports · 2026Article
- ReportedFEMS microbes · 2026Article
312 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cryptococcosis is an invasive mycosis caused by pathogenic encapsulated yeasts in the genus Cryptococcus. Cryptococcus gained prominence as a pathogen capable of widespread disease outbreaks in vulnerable populations. We have gained insight into the pathobiology of Cryptococcus, including the yeast' s capacity to adapt to environmental pressures, exploit new geographic environments, and cause disease in both immunocompromised and apparently immunocompetent hosts. Inexpensive, point-of-care testing makes diagnosis more feasible than ever. The associated worldwide burden and mortality remains unacceptably high. Novel screening strategies and preemptive therapy offer promise at making a sustained and much needed impact on this sugar-coated opportunistic mycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.